Divi’s Laboratories shares jumped 4% to a fresh 52-week high of Rs 8,500 on Monday after Q1 FY27 net profit surged 65.5% to Rs 902 crore.

The headline print was hard to miss. Revenue rose 27.8% year-on-year to Rs 3,080 crore. EBITDA jumped around 72%, pushing the operating margin up to 40.75%, its best in several quarters.

Custom synthesis did the heavy lifting here. The segment now accounts for close to 60% of Divi’s revenue, and grew sharply from a year ago.

A good chunk of that came from validation batch supplies, essentially trial production runs the company carries out as new manufacturing projects move toward full commercial scale. On the call, management did not lose control.

It kept its guidance of double-digit revenue growth for the year but was upfront that results could stay bumpy quarter to quarter, since the custom synthesis business runs on project timelines rather than steady output.

Full-year gross margin is also expected to settle nearer 60%, down from the 68% booked this quarter.

Zoom out and the stock’s run has been strong through 2026: up over 32% year to date and more than 125% across three years, per NSE data.

Monday’s high of Rs 8,500 sits well above its 52-week low of Rs 5,636.50, touched back in September.

By 9:56 am, Divi’s Laboratories was changing hands at Rs 8,393 on the NSE, holding onto that 4.18% gain.

Feeling overwhelmed by the markets? Let Tradz by EquityPandit be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!